WO2020183332A1 - Purification d'adalimumab à l'aide d'une chromatographie en tandem - Google Patents

Purification d'adalimumab à l'aide d'une chromatographie en tandem Download PDF

Info

Publication number
WO2020183332A1
WO2020183332A1 PCT/IB2020/051992 IB2020051992W WO2020183332A1 WO 2020183332 A1 WO2020183332 A1 WO 2020183332A1 IB 2020051992 W IB2020051992 W IB 2020051992W WO 2020183332 A1 WO2020183332 A1 WO 2020183332A1
Authority
WO
WIPO (PCT)
Prior art keywords
chromatography
adalimumab
purification
aex
protein
Prior art date
Application number
PCT/IB2020/051992
Other languages
English (en)
Inventor
Sridevi KHAMBHAMPATY
Shraddha SRINATH
Monami PAUL
Nivedita
Irshad GANDHI
Anoop Vasudevan
Original Assignee
Intas Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd. filed Critical Intas Pharmaceuticals Ltd.
Publication of WO2020183332A1 publication Critical patent/WO2020183332A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention provides a novel process for the purification of Adalimumab obtained from a fermentation harvest of CHO cell culture expressing said Adalimumab.
  • the present invention further provides a novel purification process of Adalimumab by employing AEX-CEX tandem chromatography technique in a unique manner to obtain a highly purified preparation of Adalimumab while potentially preventing the formation as well as clearing of impurities such as aggregate species.
  • the present invention also provides a highly scalable, reproducible and cost effective process for purification of Adalimumab.
  • Tumor necrosis factor is a polypeptide cytokine involved in inflammatory and the acute phase responses. TNF-alpha is present in larger quantities in persons with rheumatoid arthritis or Crohn's disease. It is also involved in Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PA), Ankylosing Spondylitis (AS), Ulcerative Colitis and Plaque Psoriasis. Direct inhibition of TNF-alpha by the biological agents has produced significant advances in the treatment of rheumatoid arthritis and other auto-immune disease and has validated the extra-cellular inhibition of this pro- inflammatory cytokine as an effective therapy.
  • One such biological agent is Adalimumab.
  • Adalimumab (Anti-TNFa antibody), marketed as HUMIRA® by Abott Inc., is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF).
  • Adalimumab was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl constant regions.
  • Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
  • US8946395 discloses method for purifying Adalimumab from a composition comprising the antibody and a contaminant having a reduced level of at least one impurity, comprising hydrophobic interaction chromatography (HIC) step.
  • HIC hydrophobic interaction chromatography
  • US9109010 discloses method for producing host cell protein reduced antibody comprising low pH treatment, ion exchange chromatography and HIC chromatography, wherein sample mixture is not exposed to protein A.
  • US6417335 discloses method for purifying an antibody from a composition comprising the antibody and a contaminant, which method comprises: (a) loading the composition onto a cation exchange resin, wherein the amount of antibody loaded onto the cation exchange resin is from about 20 mg to about 35 mg of the antibody per mL of cation exchange resin; and (b) eluting the antibody from the cation exchange resin.
  • US7863426 discloses method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
  • purification protocols In order to attain the appropriate degree of purity for the commercial use of therapeutic and diagnostic proteins, purification protocols often require use of two or more chromatographic purification steps. Challenges are presented by more complex purification schemes. For example, product pools processed by one purification mode must be made compatible for processing in a second purification mode. Also, partially processed product pools must be properly stored when downstream purification systems are not immediately available for use. Multiple systems necessitate multiple sampling and validation steps to ensure consistent and proper operation. Systems that integrate multiple purification modes would potentially reduce the complexity of current purification schemes, thereby enhancing the efficiency and reducing the cost of handling manufactured proteins.
  • Protein aggregation is a common phenomenon that can be encountered during various stages of a commercial antibody manufacturing processes. For example, aggregates can form during the fermentation, purification, final formulation operations, or as a result of the storage of the drug substance or final drug product.
  • Downstream processing has been estimated to account for 50 to 80% of the total manufacturing costs of therapeutic antibodies.
  • Numerous strategies have been developed to minimize antibody aggregation during the upstream and downstream unit operations required for antibody manufacturing including optimization of media components, culture feed conditions and operating parameters, genetic engineering of host cell/expression systems, protein engineering, formulation buffer screening and separation during downstream processing.
  • separation of aggregates from drug substance using a downstream manufacturing step (unit operation) that is optimized for a particular protein of interest (POI) is a popular strategy which affords an opportunity to remove aggregates from the drug substance once they have been generated.
  • Adalimumab by decreasing formation of impurities such as aggregate species or charge variants to achieve higher final concentrations along with minimizing yield loss and impact on processing time. Also it would be preferred to have a purification method for Adalimumab by which holding at intermediate stage is avoided that potentially prevents formation of aggregate species, thereby providing better control on the quality of the product.
  • present invention eliminate the chances of increase in bioburden and bacterial endotoxin between the steps and thus eliminates additional steps during purification and helps in increasing the manufacturing ease and reducing processing time and cost.
  • the principal object of the present invention is to provide a novel process for purification of Adalimumab with decreased formation of impurities such as aggregates, through chromatographically contacting the sample with AEX-CEX tandem chromatography followed by subsequent purification steps.
  • Another objective of the present invention is to provide a novel process for purification of Adalimumab through AEX-CEX tandem chromatography followed by subsequent purification steps.
  • Another objective of the present invention is to provide a novel process for purification of Adalimumab through AEX-CEX tandem chromatography followed by subsequent purification steps wherein AEX-CEX tandem chromatography is preceded by protein A chromatography, low pH treatment and depth filtration step.
  • Another object of the present invention is to provide a novel process for purifying Adalimumab from a fermentation harvest of a Chinese Hamster Ovary (CHO) cell culture expressing said Adalimumab, said process comprising:
  • Another objective of the present invention is to provide cost effective novel process for purification Adalimumab, wherein said method comprising the steps of:
  • Another objective of the present invention is to provide cost effective novel process for purification Adalimumab, wherein said method comprising the steps of:
  • the principal aspect of the present invention is to provide a novel process for purification of Adalimumab with decreased formation of impurities such as aggregate species through chromatographically contacting the sample with AEX- CEX tandem chromatography followed by subsequent purification steps.
  • Another aspect of the present invention is to provide cost effective novel process for purification Adalimumab, wherein said method comprising the steps of:
  • Another aspect of the present invention is to provide cost effective novel process for purification Adalimumab, wherein said method comprising the steps of:
  • Aggregates in therapeutic monoclonal antibody (mAh) drug products can be viewed as an evolving mixture of various types which can actively undergo transition under equilibrium states. At any given time, the heterogeneous molecular forms present in in such a mixture may reach a new equilibrium and transform into an even larger aggregate or complex structure. Once the higher order structure of a protein is disrupted, non-native interactions of exposed hydrophobic regions can promote intermolecular interactions leading to aggregation, or in some cases, precipitation.
  • Protein aggregates can be classified in several ways, including soluble/insoluble, covalent/non-covalent, reversible/non-reversible, and native/denatured. Soluble aggregates refer to those that are not visible as discrete particles and that may not be removed by a 0.22 pm filter. Conversely, insoluble aggregates may be removed by filtration and are often visible to the unaided eye. Covalent aggregates arise from the formation of a chemical bond between two or more monomers, or result from the chemical linking of partially unfolded molecules with each other. Disulfide bond formation resulting from previously unpaired free thiols is a common mechanism for covalent aggregation.
  • Oxidation of tyrosines may also result in covalent aggregation through the formation of bityrosine.
  • Reversible protein aggregation typically results from relatively weak noncovalent protein interactions. The reversibility is sometimes indicative of the presence of equilibrium between the monomer and higher order forms. This equilibrium may shift as a result of a change in solution conditions such as a decrease in protein concentration or a change in pH.
  • aggregates refers to protein aggregates. It encompasses multimers (such as dimers, tetramers or higher order aggregates) of the mAh to be purified and may result e.g. in high molecular weight aggregates.
  • charge variants refers to the full complement of product variants including, but not limited to acidic species and basic species (e.g., Lys variants).
  • such variants can include product aggregates and/or product fragments, to the extent that such aggregation and/or fragmentation results in a product charge variation.
  • the term “acidic variant” refers to a variant or isoform of the antibody of interest which is more acidic and has a lower pi value than the antibody of interest.
  • basic variant refers to a variant or isoform of the antibody of interest which is more basic and has a higher pi value than the antibody of interest.
  • a “high-molecular- weight- species” or “HMW” comprises a preparation of Adalimumab having a molecular weight that is greater than the main species or intact Adalimumab.
  • A“low-molecular-weight-species” or“LMW” of Adalimumab comprises a fragment of Adalimumab that has a molecular weight less than that of main species or intact Adalimumab.
  • flow-through process refers to a product separation technique in which at least one product (monomeric mAh) contained in a sample along with one or more contaminants is intended to flow through a chromatographic resin or media, while at least one potential contaminant or impurity binds to the chromatographic resin or media.
  • the "flow- through mode” is generally an isocratic operation (i.e., a chromatography process during which the composition of the mobile phase is not changed).
  • binding and elute mode and "bind and elute process,” as used interchangeably herein, refer to a product separation technique in which at least one product contained in a sample (e.g., an Fc region containing protein) binds to a chromatographic resin or media and is subsequently eluted.
  • a sample e.g., an Fc region containing protein
  • ultrafiltration refers to membrane filtration technique which employs controlled pore, semi permeable membranes to concentrate or fractionate dissolved molecules. Molecules much larger than the pores are retained in the feed solution and are concentrated in direct proportion to the volume of liquid that passes through the membrane. Molecules having a size which is close to the pore size of the membrane concentrate to a lesser extent with some of the molecules passing through the membrane in the permeate. The concentration of freely permeable molecules (salts) in the sample remains essentially unchanged.
  • Membranes suitable for ultrafiltration (referred to as ultrafiltration or UF membranes) are defined by the molecular weight cut-off (MWCO) of the membrane used. Ultrafiltration can be applied in cross-flow or dead-end mode.
  • diafiltration refers to a technique that uses ultrafiltration membranes to completely remove, replace or lower the concentration of salts or solvents from solutions containing proteins, peptides, nucleic acids, and other biomolecules.
  • the process selectively utilizes permeable (porous) membrane filters to separate the components of solutions and suspensions based on their molecular size.
  • An ultrafiltration membrane retains molecules that are larger than the pores of the membrane while smaller molecules such as salts, solvents and water, which are 100% permeable, freely pass through the membrane.
  • buffer is introduced into the recycle tank while filtrate is removed from the unit operation.
  • diafiltration washes components out of the product pool into the filtrate, thereby exchanging buffers and reducing the concentration of undesirable species.
  • diafiltration washes it through the membrane into a collection vessel.
  • TFF Tangential Flow Filtration
  • permeate Biological materials and particulates that are too large to pass through the membrane pores are retained on the upstream side (referred to as retentate).
  • retentate upstream side
  • the retained materials do not build up at the surface of the membrane. Instead, they are swept along the face of the membrane by tangential flow of fluid.
  • TFF may also be referred to as“cross-flow filtration.”
  • the platform process for purification of monoclonal antibodies involve capturing of the target protein secreted by CHO cells using a protein-A affinity chromatography column, a low pH treatment for inactivation of virus particles, one to three chromatographic steps with orthogonal working principles to separate the target molecule from different impurities such as size variants, charge variants, etc., followed by ultrafiltration and/or diafiltration, nanofiltration and sterile filtration, as required.
  • the principal embodiment of the present invention is to provide a novel process for purification of Adalimumab with decreased formation of impurities such as aggregate species through chromatographically contacting the sample with AEX- CEX tandem chromatography followed by subsequent purification steps.
  • Another embodiment of the present invention is to provide a novel process for purification of Adalimumab through AEX-CEX tandem chromatography followed by subsequent purification steps.
  • Another embodiment of the present invention is to provide a novel process for purification of Adalimumab through AEX-CEX tandem chromatography followed by subsequent purification steps wherein AEX-CEX tandem chromatography is preceded by protein A chromatography and low pH treatment step.
  • Another embodiment of the present invention is to provide a novel process for purifying Adalimumab from a fermentation harvest of a Chinese Hamster Ovary (CHO) cell culture expressing said Adalimumab, said process comprising:
  • Another embodiment of the present invention is to provide cost effective novel process for purification Adalimumab, wherein said method comprising the steps of: a) Protein A chromatography;
  • Another embodiment of the present invention is to provide cost effective novel process for purification Adalimumab, wherein said method comprising the steps of: a) Protein A chromatography;
  • one of the chromatographic steps used during the purification is anion exchange chromatography and cation exchange chromatography in tandem mode.
  • Anion exchange chromatography is done in flow through mode where process-related impurities such as HCP, viral particles and product-related impurities such as size variants get adsorbed on to the column and the target protein, i.e., Adalimumab, will not get adsorbed when the loading of protein mixture is done at pH less than the isoelectric pH of Adalimumab (approximately 8.2).
  • Cation exchange chromatography is done at bind-elute mode where binding happens at pH below the isoelectric pH of Adalimumab and elution is facilitated by increasing the salt concentration along with a change in pH.
  • the elution conditions are chosen such that our protein of interest, Adalimumab, is selectively eluted, resulting in separation of product-related impurities such as size variants.
  • the cation exchange output thus will have higher purity and lower levels of impurities.
  • the target levels of impurities at this stage will be such that the product will match with the impurity profile of innovator (Brand name: Humira®) at the drug product stage.
  • Clarified cell culture harvest is loaded on to the protein A chromatography resin with equilibration buffer (5-15 CVs) having 5-20mM tris-acetate, 100-130mM NaCl and l-5mM EDTA having pH of about 7.0-8.0 and conductivity of about 10-20mS/cm.
  • Post load equilibration is carried out with 5-15 CV of same equilibration buffer followed by high salt wash with 2-lOCVs of high salt wash buffer (10-20mM tris-acetate, 1-2 M NaCl having pH of about 7.0-8.0, Conductivity of about 80-110 mS/cm).
  • low pH wash with 7-15 CVs of low pH wash buffer (10-20 mM tris-acetate pH of about 6.0-7.0, Conductivity of about 0.2-1.0 mS/cm) is performed. Finally the elution is performed with elution buffer (200-300 mM tris-acetate pH of about 3.0- 4.0, Conductivity of about 0.2-1.0 mS/cm). Protein A chromatography output is subjected to low pH treatment at pH of about 3.0-4.0 at temperature: (25 ⁇ 2) °C, for (60 ⁇ 10) min followed by neutralization to pH 7.0 with 1M Tris. After low pH treatment depth filtration is performed.
  • the stationary phase media used at anion exchange step is cross-linked agarose with the ligand quaternary amine, although other stationary phase media such as cross-linked cellulose or polymeric media with similar ligands can be used.
  • the anion exchange column is first equilibrated with 5- 25 CVs of equilibration buffer 10-20 mM Tris-acetate (pH about 7.0-8.0; conductivity about 1-10 mS/cm) followed by loading of the protein mixture with binding capacity ⁇ 120 mg/ml of resin. The flow through from the anion exchange chromatography is collected and loaded to a cation exchange chromatographic column.
  • the stationary phase media used at cation exchange step is polymeric media with the ligand containing sulphoisobutyl group, although other stationary phase media such as cross-linked agarose or cellulose with similar ligands can be used.
  • the cation exchange column is first equilibrated with 5-25 CVs of equilibration buffer 20-40 mM Tris-acetate (pH about 7.0-8.0; conductivity about 1-10 mS/cm) followed by loading of the protein mixture with binding capacity ⁇ 120 mg/ml of resin.
  • the loaded protein at cation exchange stage gets bound to the column and washed with 5 - 10 CVs of equilibration buffer 20-40 mM Tris-acetate (pH about 4.0-6.0; conductivity about 1-5 mS/cm). After washing, the protein of interest is eluted using 10-25CVs of 0.4-1 M Tris-acetate (pH about 5.0-6.0; conductivity about 1-5 mS/cm).
  • the major feature of current invention is, with the above chromatographic conditions, the flow through from anion exchange chromatographic column can be directly loaded on to the second column - the cation exchange chromatographic column - without any treatment such as dilution or pH adjustment.
  • This enables the two chromatographic column procedures to be used in tandem mode, where the outlet of first chromatographic column is directly connected to the inlet of second chromatographic column.
  • holding at intermediate stage is avoided that potentially prevents formation of impurities such as aggregate species, thereby providing a better control on the quality of the product.
  • Example 1 Purification of Adalimumab through non-tandem mode chromatographic process
  • Adalimumab purification process starts with cell culture supernatant / clarified broth containing the product.
  • the cell culture supernatant was obtained after clarification of cell culture harvest produced at bioreactor in upstream.
  • the purification process was based on three chromatographic techniques: Protein A chromatography, anion exchange chromatography and cation exchange chromatography; and one ultrafiltration diafiltration (UFDF)/tangential flow filtration (TFF) step.
  • UFDF ultrafiltration diafiltration
  • TMF tangential flow filtration
  • the Protein A chromatography was employed as the capture step in mAb purification process because of its specificity for the fragment-crystallisable (Fc) region of antibodies.
  • IgG binds to Protein A ligand through affinity interactions. This step removes majority of the host related (HCPs, HCD, potential endotoxin like contaminants, viruses and virus like particles) and process related (media components and coloring matter) impurities with a very high yield (> 90%).
  • Low pH treatment was performed to inactivate enveloped viruses at pH 3.5 for ⁇ 60 min. This step is performed immediately after the Protein A elution to inactivate enveloped viruses, if any.
  • Neutralization was performed to adjust the pH and conductivity conditions for loading on anion exchange chromatography. After neutralization depth filtration is performed to control turbidity.
  • DFOP depth filter output
  • Anion exchange chromatography was run in flow through mode where process-related impurities such as HCP, viral particles and product-related impurities such as size variants get adsorbed on to the column and the target protein, i.e., Adalimumab, will not get adsorbed when the loading of protein mixture is done at pH less than the isoelectric point of Adalimumab (approximately 8.4).
  • Adalimumab target protein
  • eluate can be stored till further chromatographic step. This holding at intermediate stage increases chances of increase in bioburden and bacterial endotoxin between the two steps.
  • anion exchange chromatography output was loaded onto cation exchange chromatography column.
  • Cation exchange chromatography is operated in bind elute mode.
  • the cation exchange chromatography output was then subjected to ultrafiltration diafiltration (UFDF)/Tangential flow filtration (TFF) to obtain the product in the final formulation buffer and target drug substance concentration.
  • UDF ultrafiltration diafiltration
  • TTF Tangential flow filtration
  • This step was followed by 0.2m filtration to obtain drug substance.
  • This drug substance was then stored at -20°C.
  • Table: 1 and Table: 2 represents product quality in terms of size variants and product quality in terms of charge variants respectively, through non-tandem mode chromatographic process.
  • Table: 1 Product quality in terms of size variants in non-tandem mode purification process
  • Example 2 Purification of Adalimumab through tandem mode chromatographic process
  • Adalimumab purification process starts with cell culture supernatant /clarified broth containing the product.
  • the cell culture supernatant is obtained after clarification of cell culture harvest produced at bioreactor in upstream.
  • the purification process is based on three chromatographic techniques: Protein A chromatography, Anion exchange chromatography and Cation exchange chromatography (in tandem); and one ultrafiltration diafiltration (UFDF)/tangential flow filtration (TFF) step.
  • UFDF ultrafiltration diafiltration
  • TMF tangential flow filtration
  • the Depth filter output (DFOP) was then loaded onto AEX-CEX, which were connected in tandem.
  • AEX was operated in flow through mode and CEX was operated in bind elute mode.
  • the loaded protein flows through the AEX column and binds directly on to the CEX resin under the given flow, pH and conductivity conditions.
  • the AEX step provides clearance of impurities such as HCD (Host cell DNA) and viruses that bind to the column, whereas the protein does not bind under the existing pH.
  • Cation exchange chromatography provides a complementary chemistry, charge based binding and charge and salt based elution which allows most of the negatively charged impurities such as host cell proteins, residual DNA, residual leached Protein A and bacterial endotoxins to be removed in flow through and wash fractions, while the target product remains bound to the resin.
  • CEX chromatography may also separate aggregates, low molecular weight/ degraded/ truncated impurities from the target product. Thus the combination of these two steps removes most of the product related and process related impurities and yields the product with purity more than 98 %.
  • the AEX-CEX output was then subjected to ultrafiltration diafiltration (UFDF)/Tangential flow filtration (TFF) to obtain the product in the final formulation buffer and target drug substance concentration. This step was followed by 0.2m filtration to obtain drug substance. This drug substance was then stored at - 20°C.
  • Table: 3 and Table: 4 represents product quality in terms of size variants and product quality in terms of charge variants respectively, through tandem mode chromatographic process.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau procédé de purification d'adalimumab obtenu à partir d'une récolte de fermentation de culture de cellules CHO exprimant ledit adalimumab. La présente invention concerne en outre un nouveau procédé de purification d'adalimumab au moyen d'une technique de chromatographie en tandem AEX-CEX d'une manière unique pour obtenir une préparation hautement purifiée d'adalimumab tout en empêchant potentiellement la formation ainsi que l'élimination d'impuretés telles que des espèces agrégées. La présente invention concerne également un procédé hautement évolutif, reproductible et rentable de purification d'adalimumab.
PCT/IB2020/051992 2019-03-11 2020-03-07 Purification d'adalimumab à l'aide d'une chromatographie en tandem WO2020183332A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921009334 2019-03-11
IN201921009334 2019-03-11

Publications (1)

Publication Number Publication Date
WO2020183332A1 true WO2020183332A1 (fr) 2020-09-17

Family

ID=72427803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/051992 WO2020183332A1 (fr) 2019-03-11 2020-03-07 Purification d'adalimumab à l'aide d'une chromatographie en tandem

Country Status (1)

Country Link
WO (1) WO2020183332A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023180523A1 (fr) * 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Procédé de purification de protéines de fusion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059308A1 (fr) * 2010-11-01 2012-05-10 Dsm Ip Assets B.V. Purification d'anticorps par chromatographie échangeuse d'ions dans une unité simple
US20160083454A1 (en) * 2013-05-06 2016-03-24 Sanofi Continuous multistep process for purifying antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059308A1 (fr) * 2010-11-01 2012-05-10 Dsm Ip Assets B.V. Purification d'anticorps par chromatographie échangeuse d'ions dans une unité simple
US20160083454A1 (en) * 2013-05-06 2016-03-24 Sanofi Continuous multistep process for purifying antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ICHIHARA T ET AL.: "Polishing approach with fully connected flow-through purification for therapeutic monoclonal antibody", ENGINEERING IN LIFE SCIENCES, vol. 19, no. l, 4 October 2018 (2018-10-04), pages 31 - 36, XP055739323 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023180523A1 (fr) * 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Procédé de purification de protéines de fusion

Similar Documents

Publication Publication Date Title
AU2011214361B2 (en) Single unit antibody purification
JP6471183B2 (ja) 生体分子の精製
KR101484659B1 (ko) 단백질 정제하는 동안 샘플 중의 하나 이상의 불순물 양을 감소시키는 방법
AU2011325341B2 (en) Single unit ion exchange chromatography antibody purification
WO2009135656A1 (fr) Procédé de purification d’anticorps à l’aide de la chromatographie de déplacement
WO2014102814A1 (fr) Procédé de purification de protéines de fusion fc
WO2020183332A1 (fr) Purification d'adalimumab à l'aide d'une chromatographie en tandem
AU2012269240B2 (en) Single unit chromatography antibody purification
JP2023515521A (ja) ベバシズマブ精製の最適化された方法
CA2772846A1 (fr) Reglage de filtration prealable de solutes issus de tampon
US20230182041A1 (en) Purification of antibodies
WO2011015919A1 (fr) Procédé hautement efficace pour la purification et la production d'infliximab de recombinaison
Vaskó et al. Development and Comparison of Alternative Methods for the Purification of Adalimumab Directly from Harvested Cell Culture Fluid
CN115819608A (zh) 一种纯化融合蛋白的方法
WO2024026446A1 (fr) Procédé de purification d'un polypeptide comprenant deux étapes imac et appareil correspondant
CA3095850A1 (fr) Milieux de chromatographie cex et elution a faible teneur en sel de proteines cibles a partir de flux bio-pharmaceutiques
CN115734969A (zh) 双特异性抗体的纯化
TW201302777A (zh) 單一單元層析法抗體純化技術

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20770751

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20770751

Country of ref document: EP

Kind code of ref document: A1